This is epitomized by the application of ErbB2‐targeted drugs in a subset of breast cancers, of BRAF inhibitors in melanomas, of drugs targeting liabilities due to mutated BRCA in gynecological tumors, to cite some key examples. Here, BRAF is linked to female reproductive system neoplasm.